This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Sep;4(9):510-1.

doi: 10.1038/ncponc0902. Epub 2007 Jul 10.

To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer

Giuseppe Curigliano¹, Aron Goldhirsch

Affiliations

PMID: 17622232
DOI: 10.1038/ncponc0902

Comment

To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer

Giuseppe Curigliano et al. Nat Clin Pract Oncol. 2007 Sep.

. 2007 Sep;4(9):510-1.

doi: 10.1038/ncponc0902. Epub 2007 Jul 10.

Authors

Giuseppe Curigliano¹, Aron Goldhirsch

Affiliation

¹ Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy.

PMID: 17622232
DOI: 10.1038/ncponc0902

No abstract available

PubMed Disclaimer

Comment on

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Coombes RC, et al. Lancet. 2007 Feb 17;369(9561):559-70. doi: 10.1016/S0140-6736(07)60200-1. Lancet. 2007. PMID: 17307102 Clinical Trial.

Similar articles

Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N, Paridaens R, Cufer T. Snoj N, et al. Curr Opin Oncol. 2008 Nov;20(6):627-33. doi: 10.1097/CCO.0b013e3283136770. Curr Opin Oncol. 2008. PMID: 18841043 Review.
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R. Carpenter R. Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Eur J Surg Oncol. 2008. PMID: 18296017 Review.
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393. J Clin Oncol. 2008. PMID: 18349391 Clinical Trial.
New criteria for selecting elderly patients for breast cancer adjuvant treatment studies.
Dellapasqua S, Colleoni M, Castiglione M, Goldhirsch A. Dellapasqua S, et al. Oncologist. 2007 Aug;12(8):952-9. doi: 10.1634/theoncologist.12-8-952. Oncologist. 2007. PMID: 17766654
Adjuvant endocrine therapy in post menopausal women: pharmacological evaluation using decision analysis approach in a Japanese hospital setting.
Miyazaki Y, Arakawa I, Inoue T. Miyazaki Y, et al. Gan To Kagaku Ryoho. 2009 Aug;36(8):1299-309. Gan To Kagaku Ryoho. 2009. PMID: 19692769

See all similar articles

Cited by

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Ballinger TJ, Meier JB, Jansen VM. Ballinger TJ, et al. Front Oncol. 2018 Aug 10;8:308. doi: 10.3389/fonc.2018.00308. eCollection 2018. Front Oncol. 2018. PMID: 30148117 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.